Skip to main content
Top
Published in: Journal of Medical Case Reports 1/2018

Open Access 01-12-2018 | Case report

Extensive abdominal wall ulceration as a late manifestation of antiphospholipid syndrome: a case report

Authors: Yogesh Sharma, Karen Humphreys, Campbell Thompson

Published in: Journal of Medical Case Reports | Issue 1/2018

Login to get access

Abstract

Background

Antiphospholipid syndrome is an autoimmune disorder characterized by the presence of antiphospholipid antibodies and commonly presents with vascular thromboembolic phenomena, thrombocytopenia, and obstetric complications. Antiphospholipid syndrome can be classified as either primary or secondary to other connective tissue diseases. Dermatologic manifestations are common; however, non-vasculitic skin ulceration is an uncommon manifestation of antiphospholipid syndrome with limited treatment options.

Case presentation

In this paper we report the case of a 58-year-old white woman who developed necrotic abdominal wall ulcers 27 years after a diagnosis of secondary antiphospholipid syndrome associated with systemic lupus erythematosus. The ulcers developed despite our patient being on therapeutic anticoagulation with warfarin and were resistant to further increases in the intensity of anticoagulation. Management was further complicated due to reluctance on the part of our patient to switch over to injectable heparin.

Conclusions

This case highlights a rare late dermatologic presentation of antiphospholipid syndrome, which responded poorly to conventional anticoagulation with warfarin. Current management is limited to experimental therapies and the role of newer anticoagulants is still unknown.
Literature
1.
go back to reference Kutteh WH, Hinote CD. Antiphospholipid antibody syndrome. Obstet Gynecol Clin N Am. 2014;41:113–32.CrossRef Kutteh WH, Hinote CD. Antiphospholipid antibody syndrome. Obstet Gynecol Clin N Am. 2014;41:113–32.CrossRef
2.
go back to reference Erkan D, Aguiar CL, Andrade D, Cohen H, Cuadrado MJ, Danowski A, Levy RA, Ortel TL, Rahman A, Salmon JE, Tektonidou MG, Willis R, Lockshin MD. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev. 2014;13:685–96.CrossRefPubMed Erkan D, Aguiar CL, Andrade D, Cohen H, Cuadrado MJ, Danowski A, Levy RA, Ortel TL, Rahman A, Salmon JE, Tektonidou MG, Willis R, Lockshin MD. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev. 2014;13:685–96.CrossRefPubMed
3.
go back to reference Erkan D, Lockshin MD. Non-criteria manifestations of antiphospholipid syndrome. Lupus. 2010;19:424–7.CrossRefPubMed Erkan D, Lockshin MD. Non-criteria manifestations of antiphospholipid syndrome. Lupus. 2010;19:424–7.CrossRefPubMed
5.
go back to reference Somers E, Magder LS, Petri M. Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus. J Rheumatol. 2002;29:2531–6.PubMed Somers E, Magder LS, Petri M. Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus. J Rheumatol. 2002;29:2531–6.PubMed
6.
go back to reference Arachchillage DR, Machin SJ, Mackie IJ, Cohen H. Diagnosis and management of non-criteria obstetric antiphospholipid syndrome. Thromb Haemost. 2015;113:13–9.CrossRefPubMed Arachchillage DR, Machin SJ, Mackie IJ, Cohen H. Diagnosis and management of non-criteria obstetric antiphospholipid syndrome. Thromb Haemost. 2015;113:13–9.CrossRefPubMed
7.
go back to reference Frances C, Niang S, Laffitte E, Pelletier F, Costedoat N, Piette JC. Dermatologic manifestations of the antiphospholipid syndrome: two hundred consecutive cases. Arthritis Rheum. 2005;52:1785–93.CrossRefPubMed Frances C, Niang S, Laffitte E, Pelletier F, Costedoat N, Piette JC. Dermatologic manifestations of the antiphospholipid syndrome: two hundred consecutive cases. Arthritis Rheum. 2005;52:1785–93.CrossRefPubMed
8.
go back to reference Asherson RA, Frances C, Iaccarino L, Khamashta MA, Malacarne F, Piette JC, Tincani A, Doria A. The antiphospholipid antibody syndrome: diagnosis, skin manifestations and current therapy. Clin Exp Rheumatol. 2006;24:S46–51.PubMed Asherson RA, Frances C, Iaccarino L, Khamashta MA, Malacarne F, Piette JC, Tincani A, Doria A. The antiphospholipid antibody syndrome: diagnosis, skin manifestations and current therapy. Clin Exp Rheumatol. 2006;24:S46–51.PubMed
9.
go back to reference Frances C, Barete S, Soria A. Dermatologic manifestations of the antiphospholipid syndrome. Rev Med Interne. 2012;33:200–5.CrossRefPubMed Frances C, Barete S, Soria A. Dermatologic manifestations of the antiphospholipid syndrome. Rev Med Interne. 2012;33:200–5.CrossRefPubMed
10.
go back to reference Rodriguez-Pinto I, Espinosa G, Cervera R. Catastrophic antiphospholipid syndrome: the current management approach. Best Pract Res Clin Rheumatol. 2016;30:239–49.CrossRefPubMed Rodriguez-Pinto I, Espinosa G, Cervera R. Catastrophic antiphospholipid syndrome: the current management approach. Best Pract Res Clin Rheumatol. 2016;30:239–49.CrossRefPubMed
12.
go back to reference Rosa RF, Ugolini-Lopes MR, Zeinad-Valim AK, D’Amico E, Andrade D. Difficult clinical situations in the antiphospholipid syndrome. Curr Rheumatol Rep. 2015;17:29.CrossRefPubMed Rosa RF, Ugolini-Lopes MR, Zeinad-Valim AK, D’Amico E, Andrade D. Difficult clinical situations in the antiphospholipid syndrome. Curr Rheumatol Rep. 2015;17:29.CrossRefPubMed
13.
go back to reference Acland KM, Darvay A, Wakelin SH, Russell-Jones R. Livedoid vasculitis: a manifestation of the antiphospholipid syndrome? Br J Dermatol. 1999;140:131–5.CrossRefPubMed Acland KM, Darvay A, Wakelin SH, Russell-Jones R. Livedoid vasculitis: a manifestation of the antiphospholipid syndrome? Br J Dermatol. 1999;140:131–5.CrossRefPubMed
15.
go back to reference Loidi Pascual L, Valcayo Penalba A, Oscoz Jaime S, Cordoba Iturriagagoitia A, Rodil Fraile R, Yanguas Bayona JI. Calciphylaxis. A review of 9 cases. Med Clin. 2016;147:157–61.CrossRef Loidi Pascual L, Valcayo Penalba A, Oscoz Jaime S, Cordoba Iturriagagoitia A, Rodil Fraile R, Yanguas Bayona JI. Calciphylaxis. A review of 9 cases. Med Clin. 2016;147:157–61.CrossRef
16.
go back to reference Tamayo-Isla RA, Cuba de la Cruz M. Calciphylaxis in end-stage renal disease prior to dialytic treatment: a case report and literature review. Int J Nephrol Renovasc Dis. 2015;8:13–8.CrossRefPubMedPubMedCentral Tamayo-Isla RA, Cuba de la Cruz M. Calciphylaxis in end-stage renal disease prior to dialytic treatment: a case report and literature review. Int J Nephrol Renovasc Dis. 2015;8:13–8.CrossRefPubMedPubMedCentral
18.
go back to reference Micieli R, Alavi A. Treatment for Livedoid vasculopathy: a systematic review. JAMA Dermatol. 2018;154:193–202.CrossRefPubMed Micieli R, Alavi A. Treatment for Livedoid vasculopathy: a systematic review. JAMA Dermatol. 2018;154:193–202.CrossRefPubMed
19.
go back to reference Markovic A. Vasculitis and vasculopathy. Acta Med Croatica. 2012;66(Suppl 1):19–24.PubMed Markovic A. Vasculitis and vasculopathy. Acta Med Croatica. 2012;66(Suppl 1):19–24.PubMed
21.
go back to reference Signorelli F, Balbi GGM, Levy RA. Catastrophic antiphospholipid syndrome: a case with unusual findings revealed in autopsy and a brief literature update. Eur J Rheumatol. 2017;4:281–3.CrossRefPubMedPubMedCentral Signorelli F, Balbi GGM, Levy RA. Catastrophic antiphospholipid syndrome: a case with unusual findings revealed in autopsy and a brief literature update. Eur J Rheumatol. 2017;4:281–3.CrossRefPubMedPubMedCentral
22.
go back to reference Berman H, Rodriguez-Pinto I, Cervera R, Morel N, Costedoat-Chalumeau N, Erkan D, Shoenfeld Y. Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev. 2013;12:1085–90.CrossRefPubMed Berman H, Rodriguez-Pinto I, Cervera R, Morel N, Costedoat-Chalumeau N, Erkan D, Shoenfeld Y. Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev. 2013;12:1085–90.CrossRefPubMed
23.
go back to reference Di Rocco M, Fantasia AR, Taro M, Loy A, Forlino A, Martini A. Systemic lupus erythematosus-like disease in a 6-year-old boy with prolidase deficiency. J Inherit Metab Dis. 2007;30:814.CrossRefPubMed Di Rocco M, Fantasia AR, Taro M, Loy A, Forlino A, Martini A. Systemic lupus erythematosus-like disease in a 6-year-old boy with prolidase deficiency. J Inherit Metab Dis. 2007;30:814.CrossRefPubMed
24.
go back to reference Butbul Aviel Y, Mandel H, Avitan Hersh E, Bergman R, Adiv OE, Luder A, et al. Prolidase deficiency associated with systemic lupus erythematosus (SLE): single site experience and literature review. Pediatr Rheumatol Online. 2012;10:18.CrossRef Butbul Aviel Y, Mandel H, Avitan Hersh E, Bergman R, Adiv OE, Luder A, et al. Prolidase deficiency associated with systemic lupus erythematosus (SLE): single site experience and literature review. Pediatr Rheumatol Online. 2012;10:18.CrossRef
25.
go back to reference Abreu MM, Danowski A, Wahl DG, Amigo MC, Tektonidou M, Pacheco MS, Fleming N, Domingues V, Sciascia S, Lyra JO, Petri M, Khamashta M, Levy RA. The relevance of “non-criteria” clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid antibodies technical task force report on Antiphospholipid syndrome clinical features. Autoimmun Rev. 2015;14:401–14.CrossRefPubMed Abreu MM, Danowski A, Wahl DG, Amigo MC, Tektonidou M, Pacheco MS, Fleming N, Domingues V, Sciascia S, Lyra JO, Petri M, Khamashta M, Levy RA. The relevance of “non-criteria” clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid antibodies technical task force report on Antiphospholipid syndrome clinical features. Autoimmun Rev. 2015;14:401–14.CrossRefPubMed
26.
go back to reference Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, Brey R, Crowther M, Derksen R, Erkan D, Krillis S, Machin S, Pengo V, Pierangeli S, Tektonidou M, Khamashta M. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus. 2011;20:206–18.CrossRefPubMed Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, Brey R, Crowther M, Derksen R, Erkan D, Krillis S, Machin S, Pengo V, Pierangeli S, Tektonidou M, Khamashta M. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus. 2011;20:206–18.CrossRefPubMed
27.
go back to reference Baglin TP, Keeling DM, Watson HG. Guidelines on oral anticoagulation (warfarin): third edition--2005 update. Br J Haematol. 2006;132:277–85.CrossRefPubMed Baglin TP, Keeling DM, Watson HG. Guidelines on oral anticoagulation (warfarin): third edition--2005 update. Br J Haematol. 2006;132:277–85.CrossRefPubMed
28.
go back to reference Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J, Laskin C, Fortin P, Anderson D, Kearon C, Clarke A, Geerts W, Forgie M, Green D, Costantini L, Yacura W, Wilson S, Gent M, Kovacs MJ. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003;349:1133–8.CrossRefPubMed Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J, Laskin C, Fortin P, Anderson D, Kearon C, Clarke A, Geerts W, Forgie M, Green D, Costantini L, Yacura W, Wilson S, Gent M, Kovacs MJ. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003;349:1133–8.CrossRefPubMed
29.
go back to reference Cohen H, Machin SJ. Antithrombotic treatment failures in antiphospholipid syndrome: the new anticoagulants? Lupus. 2010;19:486–91.CrossRefPubMed Cohen H, Machin SJ. Antithrombotic treatment failures in antiphospholipid syndrome: the new anticoagulants? Lupus. 2010;19:486–91.CrossRefPubMed
30.
go back to reference Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342–52.CrossRefPubMed Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342–52.CrossRefPubMed
31.
go back to reference van Es N, Coppens M, Schulman S, Middeldorp S, Buller HR. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood. 2014;124:1968–75.CrossRefPubMed van Es N, Coppens M, Schulman S, Middeldorp S, Buller HR. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood. 2014;124:1968–75.CrossRefPubMed
32.
go back to reference Cohen H, Hunt BJ, Efthymiou M, Arachchillage DR, Mackie IJ, Clawson S, Sylvestre Y, Machin SJ, Bertolaccini ML, Ruiz-Castellano M, Muirhead N, Dore CJ, Khamashta M, Isenberg DA. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Haematol. 2016;3:e426–36.CrossRefPubMedPubMedCentral Cohen H, Hunt BJ, Efthymiou M, Arachchillage DR, Mackie IJ, Clawson S, Sylvestre Y, Machin SJ, Bertolaccini ML, Ruiz-Castellano M, Muirhead N, Dore CJ, Khamashta M, Isenberg DA. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Haematol. 2016;3:e426–36.CrossRefPubMedPubMedCentral
33.
go back to reference Kronbichler A, Brezina B, Quintana LF, Jayne DR. Efficacy of plasma exchange and immunoadsorption in systemic lupus erythematosus and antiphospholipid syndrome: a systematic review. Autoimmun Rev. 2016;15:38–49.CrossRefPubMed Kronbichler A, Brezina B, Quintana LF, Jayne DR. Efficacy of plasma exchange and immunoadsorption in systemic lupus erythematosus and antiphospholipid syndrome: a systematic review. Autoimmun Rev. 2016;15:38–49.CrossRefPubMed
34.
go back to reference Srinivasan SK, Pittelkow MR, Cooper LT Jr. Recombinant tissue plasminogen activator for the treatment of cutaneous infarctions in antiphospholipid antibody syndrome: a case report. Angiology. 2001;52:635–9.CrossRefPubMed Srinivasan SK, Pittelkow MR, Cooper LT Jr. Recombinant tissue plasminogen activator for the treatment of cutaneous infarctions in antiphospholipid antibody syndrome: a case report. Angiology. 2001;52:635–9.CrossRefPubMed
35.
go back to reference Amital H, Levy Y, Shoenfeld Y. Use of intravenous immunoglobulin in livedo vasculitis. Clin Exp Rheumatol. 2000;18:404–6.PubMed Amital H, Levy Y, Shoenfeld Y. Use of intravenous immunoglobulin in livedo vasculitis. Clin Exp Rheumatol. 2000;18:404–6.PubMed
36.
go back to reference Gertner E. Treatment with sildenafil for the healing of refractory skin ulcerations in the antiphospholipid syndrome. Lupus. 2003;12:133–5.CrossRefPubMed Gertner E. Treatment with sildenafil for the healing of refractory skin ulcerations in the antiphospholipid syndrome. Lupus. 2003;12:133–5.CrossRefPubMed
Metadata
Title
Extensive abdominal wall ulceration as a late manifestation of antiphospholipid syndrome: a case report
Authors
Yogesh Sharma
Karen Humphreys
Campbell Thompson
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Journal of Medical Case Reports / Issue 1/2018
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/s13256-018-1753-5

Other articles of this Issue 1/2018

Journal of Medical Case Reports 1/2018 Go to the issue